|Seattle Genetics Announces ADCETRIS® Receives Positive CHMP Opinion for Conditional Approval in European Union|
Recommended as Treatment for Relapsed or Refractory Hodgkin Lymphoma and Systemic ALCL
“The positive opinion from CHMP and broad label recommendation is a key
step in the European regulatory process for ADCETRIS and brings us
closer to our goal of making this important new therapy globally
available to patients with relapsed Hodgkin lymphoma or systemic ALCL,”
ADCETRIS (brentuximab vedotin) is an ADC comprising an anti-CD30 monoclonal antibody attached by a protease-cleavable linker to a microtubule disrupting agent, monomethyl auristatin E (MMAE), utilizing Seattle Genetics’ proprietary technology. The ADC employs a linker system that is designed to be stable in the bloodstream but to release MMAE upon internalization into CD30-expressing tumor cells.
ADCETRIS received accelerated approval from the
Certain of the statements made in this press release are forward
looking, such as those, among others, relating to the potential for
approval in the
Seattle Genetics, Inc.